The synthetic antimalarial drugs in recent years have proven to play an important role in the management of lupus erythematosus and light sensitivity eruptions. The use of these drugs was originally stimulated by Page's article on the use of quinacrine (Mepacrine) in the treatment of lupus erythematosus. Light-sensitivity eruptions were also successfully treated and recurrences prevented with quinacrine and chloroquine.2,3 Leeper and Allende4 compared the use of quinacrine, chloroquine, and amodiaquin, and indicated that the latter two were preferable. Plaquenil sulfate5 was reported to be effective in these conditions with a lower incidence of side effects. Schoch,6 in a recent article, reviews the use of the antimalarial drugs in these conditions and gives an extensive bibliography.
A physician is now faced with the problem of which of the antimalarial drugs to use in order to get a maximum response
BENNETT JH, REES RB. Triquin (Triple Synthetic Antimalarial) in Dermatology: Response of Chronic Discoid Lupus Erythematosus, Light-Sensitivity Eruptions, and Miscellaneous Dermatoses. AMA Arch Derm. 1959;80(3):339–343. doi:10.1001/archderm.1959.01560210081015
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.